In summary, local treatment with ONCOS-102 induces dense infiltration of CD8+ T-cells to tumor and elicits systemic tumor-specific CD8+ T-cell responses, despite the presence of a high load of viral antigens in the tumor microenvironment. Here, CD8A is linked to neoplasm.